Skip to main content
OpenTrials
Completed

NCT Number: NCT02733198

Prognostication in Acute Pulmonary Embolism

To evaluate the effect of a prognosis-guided vs standard medical therapy in the: 1) duration of hospital stay; 2) cost-effectiveness; 3) satisfaction and quality of life; 4) in-hospital and 30-day all-cause mortality; and 5) 30-day readmissions in normotensive patients with acute symptomatic pulmonary embolism (PE).

Design: Prospective, randomized, controlled, single blind trial. Normotensive patients with acute symptomatic PE will be randomly assigned to follow a prognosis-guided treatment, or to receive usual care.

Setting: Respiratory, Medicine and Emergency Departments in 15 Spanish hospitals.

Analyses: Data for the primary and secondary end points will be analyzed according to the intention-to -treat principle. The intention-to-treat analysis will include all randomly assigned patients. For the efficacy end points, investigators will use the Mann-Whitney U test. We will also use competing risk regression models according to Fine and Gray. For the safety end points, comparisons will be made with the use of the chi-square test. Separate analyses will be done in key prespecified subgroups of patients, according to age and hospital size.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospital Ramon y Cajal, IRYCIS, Alcala de Henares University

Madrid, 28034, Spain

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Confirmed PE by objective testing
  • Signed and dated informed consent of the subject available before the start of any specific trial procedures

Exclusion criteria

  • Pregnancy
  • Haemodynamic instability
  • Contraindication to anticoagulant therapy
  • Life expectancy less than 3 months
  • Participation in other clinical trials during the present clinical trial
  • Use of a fibrinolytic agent, surgical thrombectomy, interventional (transcatheter) thrombus aspiration or lysis, or use of a cava filter to treat the index episode of PE
  • Inability to the follow-up visits

Treatment and study plan

Prognosis-guided therapy

Other

Primary outcomes

  1. Length of hospital stay

    Time frame: 30-days

Sponsors and collaborators

Lead sponsor

Ministry of Health, Spain

Other Gov

Registry information

Official study title

Effect of a Prognostic Algorithm to Reduce Length of Stay in Acute Pulmonary Embolism: a Randomized Controlled Trial

Acronym: IPEP

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
Apr 11, 2016
Registry last updated
Nov 18, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.